NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has announced positive results from its Phase 2a trial of NEO100, a drug candidate for recurrent brain cancer, according to a research update from Stonegate Capital Partners. The data, released on August 13, 2026, shows that NEO100 met its primary endpoint, with a six-month progression-free survival (PFS-6) rate of 48.9% as measured by RANO 2.0 criteria using Kaplan-Meier estimation, compared to a pre-specified benchmark of 20% (p=0.0047). Additionally, the median overall survival (OS) reached 26.09 months, and no major toxicities were reported.
The company views the survival signal as a critical readout, especially given that current salvage therapy for recurrent brain cancer typically offers only 6-9 months of survival. This significant improvement over existing options suggests that NEO100 could offer a meaningful benefit to patients. However, Stonegate notes that confirmation in a randomized study remains the next hurdle before the drug can be considered for approval.
This positive readout moves NEO100 into a potential registrational program. NeOnc intends to request a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of a registrational trial, endpoints, and the potential approval pathway. This meeting is seen as a key near-term catalyst for the company.
In addition to NEO100, the company's second asset, NEO212, has also gained regulatory momentum. The drug has received Phase 2 CMC clearance, and FDA feedback indicates a potential accelerated approval pathway. This broadens the company's pipeline and reduces reliance on a single asset.
Beyond the lead indications, NeOnc is expanding its clinical program to include meningioma and pediatric brain tumors, which could further enhance the platform's value. The company's research and development expenses increased to $2.6 million in the second quarter of 2026, up from $0.7 million in the same period last year, reflecting the expanded development activity.
While the financial results are secondary to the clinical progress, the increased spending underscores the company's commitment to advancing its pipeline. However, as development activities expand, funding remains an important consideration for the company's future operations.
Stonegate Capital Partners, which provides investor relations and equity research services, highlighted that the investment case for NeOnc is broadening beyond a single trial or asset. The platform's depth, with NEO100 and NEO212, offers longer-term optionality for investors. The full announcement, including downloadable images and bios, is available on Stonegate's website.
For business and technology leaders, this development is significant because it demonstrates tangible progress in a difficult-to-treat cancer, potentially leading to a new treatment option that could extend lives. It also illustrates the importance of FDA alignment in the drug development process and the value of a diversified pipeline in biotech investing.
As NeOnc moves forward, the company's next steps will be closely watched by the medical community and investors alike. The Type B meeting with the FDA will be a critical milestone, and the outcome could shape the future of NEO100 and the company's trajectory.
